一分钟看懂
这是一项关于Friedreich's Ataxia (FA)的I 期研究，登记的药物或干预包括SGT-212，当前状态为招募中。登记地点显示中国Los Angeles、Columbus、Philadelphia有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
SGT-212 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The University of California, Los Angeles (UCLA) · Los Angeles
- The Ohio State University · Columbus
- The Children's Hospital of Philadelphia (CHOP) · Philadelphia
公开的入选条件
- * Has history of FA symptom onset ≤25 years of age
- * Has a clinical and genetic diagnosis of FA
- * Has a staging score of ≥1 but \<6 on the Friedreich's Ataxia Rating Scale (FARS) Functional Disability Staging Score
- * Is willing to agree to the following rules for use of omaveloxolone (Skyclarys):
- 1. For a candidate who is currently taking omaveloxolone, has been on a stable dose for 12 weeks, expects to continue taking omaveloxolone at that dose throughout the study, and is willing to stop taking omaveloxolone at the direction of the Investigator or Sp
- 2. For a candidate who is not actively taking omaveloxolone, at least 12 weeks have passed since the last dose and the candidate agrees not to resume omaveloxolone during the 18-month period after SGT-212 infusion NOTE: The use of any other approved or investi
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07180355；登记信息更新于 2026-08-17。